Drug
Dnl952
Dnl952: highest development phase Phase 1, developed by Denali Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Denali Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| DNL952 NCT07354724 | Phase 1 | Late-onset Pompe Disease |
Latest
No recent events.
Follow Dnl952 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.